Innovation projects deal with the biggest social challenges in the field of health, which EIT Health wants to meet with its strong network. The aim is to achieve a rapid market penetration of innovative projects and services and to test and implement new organizational delivery processes in the European healthcare system.
The most promising ideas are developed into a commercially usable product using a multidisciplinary approach involving business, medicine, IT and other areas of knowledge.
More information about iPDM-GO can be found on this website
Diabetes Mellitus stellt eine große und mehrdimensionale Herausforderung für die Menschheit dar. Im Jahr 2017 schätzte die International Diabetes Federation (IDF), dass es weltweit rund 425 Millionen Menschen mit Diabetes gibt, deren Zahl weiter steigt. Daher ist es von entscheidender Bedeutung, kosteneffiziente Gesundheitsdienstleistungen anzubieten, die auf die individuellen Bedürfnisse und Anforderungen jedes Patienten zugeschnitten sind.
Integrated Personalized Diabetes Management Goes Europe (iPDM-GO), ist bestrebt, dieses Problem zu lösen. Es handelt sich um einen therapeutischen Ansatz, der den Behandlungsprozess strukturiert, HCPs und Patienten verbindet und digitale Werkzeuge zur Visualisierung und Analyse von Daten integriert.
Inflammatory respiratory diseases are often diagnosed too late. Every year, respiratory diseases in the EU are responsible for 600,000 deaths and 6 million hospitalizations, as well as costs of € 200 billion. ADAPT combines two innovations to develop a novel diagnostic kit that enables earlier and more accurate assessment of inflammatory respiratory diseases, enabling better intervention and personalized treatment.
More than 28 million people in Europe are visually impaired due to retinal diseases. The current diagnosis is based on the identification of a large-area change in the retina, which is usually only recognized by conventional ophthalmic instruments when the patient has already suffered an irreversible loss of vision. ASSESS is developing a revolutionary system that enables fast, non-invasive imaging of patients‘ retinal cells. By early diagnosis of retinal diseases, one of the main causes of blindness, innovation can improve treatment and increase prevention options.
External project partner:
Trier University of Applied Sciences
CLAIRE is developing an „Alexa with a doctorate“, an innovative virtual health care assistant, to tackle one of the greatest challenges in today’s intensive care units: medical knowledge and data are increasing daily – doctors and nurses spend 50% of their day in front of computer screens instead of interacting with the patient. CLAIRE’s virtual medical assistant combines the latest machine learning, natural language processing and artificial intelligence with an intuitive user interface to assist intensive care doctors and nurses with documentation, disease detection, and accurate, evidence-based treatment.
Mehr Informationen zu CLOSE finden Sie auf dieser Webseite.
Die künstliche Bauchspeicheldrüse (Artificial Pancreas, AP) nähert sich einer „technischen Heilung“ von Diabetes, indem sie den Glukosespiegel misst und mit Hilfe eines Algorithmus die richtige Insulinmenge für den Patienten bestimmt. CLOSE strebt danach, die Versorgung und Lebensqualität von Patienten mit Typ-2-Diabetes zu verbessern, indem es die AP mit entsprechenden Produkt- und Servicepaketen zur Schaffung von AP+ verbessert. Durch Hinzufügen von Training (Train-the-Trainer), telemedizinischer Beratung und Tools zur Ergebnisprognose und Leistungsmessung zu den APs wird CLOSE die Wirksamkeit der AP sowie die Erstattungsfähigkeit erhöhen.
Dieses Projekt zielt darauf ab, den ineffizienten Influenza-Versorgungspfad zu verbessern und zusätzliche Hindernisse, die einer breiten Einführung einer neuen Lösung im Wege stehen, zu überwinden. Die (cobas® Liat®) laborbasierte Testmethodikin an easy-to-use and compact solution to enable medical care for patients at risk of influenza at the bedside. Complementing the clinical pathway with Liat® will reduce hospitalizations and the potential transmission rate of the disease, the unnecessary prescription of antibiotics for viral infections, and the associated morbidity and mortality caused by secondary bacterial infections. The project will generate the clinical and economic evidence needed to support decision-making and advance technology adoption, rapidly accelerate access to the latest diagnostic technologies, and improve the impact on patients with flu.
More information about FRAIL can be found on this website
Identifying and assessing frailty in the treatment of the elderly is essential to tailor geriatric interventions to the needs of individuals. The instruments currently available for assessing individual frailty, which require time-consuming screening processes, are difficult to apply in primary care. FRAIL is a project to develop a smartwatch app that supports older people who are in a frail condition. The app monitors falls, physical activity and interruption of routine activities in order to recognize the onset of frailty and to prevent the consequences of this for the wearer.
Chronic Obstructive Pulmonary Disease (COPD) is a progressive, life-threatening pulmonary disease characterized by shortness of breath and cough. There are 250 million COPD patients worldwide and it is the fourth leading cause of death, responsible for 3 million deaths per year. HomeCare @ COPD will improve home care for people with pulmonary disease by helping patients understand RAS-Q to improve the so-called „lung in their backpack“ – the world’s first portable ventilator for long-term COPD treatment, supported by EIT Health was developed, uses.
Every year, more than 1 million EU citizens suffer from a stroke, and up to 30% suffer from homonymous hemianopia (HH), a complex visuomotor deficit caused by a stroke in the visual cortex and associated with the loss of a visual half-field . MARNIE helps treat visuomotor deficits that cause eye-hand coordination problems in patients after a stroke. A new therapy is being used, which combines ‚augmented reality glasses‘ with low-current stimulation of the skull to train the brain.
In the past decade, groundbreaking research into understanding the immune system and unlocking its anti-tumor potential has led to adoptive cell therapies with the potential to eliminate tumors that resist traditional and targeted therapies. T cell responses to mutant peptide ligands that serve as neoantigens on cancer cells have been shown to mediate anti-tumor responses. NEOSPECT will revolutionize cancer treatment by combining two novel clinical concepts: adoptive cell therapy and the targeted treatment of tumor-specific neoantigens. This combination will make it possible to manufacture patient-specific T-cell products in a cost-effective, safe and automated process ready for the clinic.
Mehr als 50 Millionen Menschen weltweit leiden an Epilepsie, die damit eine der häufigsten neurologischen Erkrankungen weltweit ist. Ungenaue Anfallsmeldungen stellen die Diagnose und Behandlung von Menschen mit Epilepsie vor große Herausforderungen. SeizeIT2 ist ein klinisch genaues Anfallserkennungssystem für Menschen mit Epilepsie. Dieses diskrete tragbare Gerät überwacht mehrere Biosignale, um eine genauere quantitative Analyse der Anfallsaktivität zu ermöglichen, so dass Menschen mit Epilepsie eine für ihren spezifischen Zustand optimierte Behandlung erhalten können.
Unanswered questions about the effectiveness, costs and market availability of medicines question the public’s trust in the pharmaceutical industry and treatments and have an impact on the sustainability of the healthcare system. One of the main reasons for this is the limited use of available data from the ‚real world‘ in both drug development and disease management. The lack of real data limits the predictive power of clinical trials and thus the quality of early decision making necessary in drug development – leading to high failure rates and even drug withdrawal from the market. RealWorld4Clinicwill accelerate the market launch of a coin-sized medical device anchored to the gastric fundus. There it collects real cardiorespiratory health data for use in drug development and telecardiology. The clinical trial market will be the stepping stone to outpatient cardiac care. The device will be enriched by remote monitoring and data evaluation, training and education as well as tools for predicting results and measuring performance.
Drug-induced cardiac and neuronal toxicities are major complications in everyday clinical practice and are the main cause of problems during early drug development and post-marketing. Since conventional drug screening is based on in vivo and in vitro animal models with limited translation capacity, there is an urgent need for translational assays that are able to robustly and reliably predict drug-induced toxicities in humans. The R2U Tox Assay Projectaims to broaden the boundaries of medical care with an innovative approach designed to strengthen the health system as a whole. Reliable detection of drug-induced toxicities with high-quality, ready-to-use toxicity tests at a moderate price will have an immediate impact on patient health by averting potentially fatal and costly side effects.
Do you have any questions about the current EIT Health Business Plan, application, training or deadlines? Here you will find answers to the most important questions about your cooperation with EIT Health Germany.
Innovation projects aim at (1) the rapid market penetration of innovative products and services and / or (2) the testing and implementation of new types of organizational and health delivery processes.
The maximum available funds of the EIT amount to 1 million euros per year and project for a maximum term of 36 months.
The EIT Health Innovation Projects support innovative approaches in the fields of biotech, medtech and digital health that have left the phase of soil research and are on the way to market approval and first customers.
We recommend the use of the CIMIT Innovation Maturity Level (IML), which measures the maturity of an innovation in four dimensions:
Ideally, you should have reached a „proof of concept“ level for all four dimensions. Further information can be found here: https://cimit.org/documents/173804/228699/Navigating+die+HealthTech+Innovation+Cycle.pdf/2257c90b-d90b-d90b-3b78-6dc9-745db401fbc6?version=1.0
Core or associate partners of at least two CLC / InnoStars must be involved in all proposals for innovation projects. The consortium must include at least one academic and one non-academic core or associate partner, ie a partner from the field of „education“ or „research“ and another partner.
You can find a list under this link: www.eithealth.eu/partners
You can involve external project partners that are not EIT Health Core or Associate Partners, such as startups and SMEs. The maximum funding for external project partners is EUR 50,000 / year.
For an EIT Health Innovation project, you can (pre) cover existing costs for the development of your innovation. These costs are known as „KIC Complementary Activities (KCA)“. The funding rate for the 25% EIT funding (= „KIC Added-Value Activity (KAVA)“) versus 75% of the funding of other resources (e.g. other public grants, internal resources etc.). In general, the EIT will cover the costs from 2015 and / or parallel to the project duration.
Example: If you apply for EIT funding of € 3 million for your innovation project, you have to prove € 9 million in costs that are covered by other resources.
If you are new to PLAZA, please reserve at least two full days. One day would help you familiarize yourself with the logic of linking work packages, costs and KPIs / outputs / deliveries. The second day is required to enter the details into the system.
The German CLC supports innovation projects from the early project idea to the final submission and evaluation.
Support includes, for example:
Do you have more questions? I would be happy to inform you about your options for participating in an EIT Health innovation project and support you in finding ideas, networking with relevant EIT Health partners, applying and in all further steps of your innovation project as part of the EIT Health Business Plan.